Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
Antimicrobial resistance
Clostridioides difficile
Meta-analysis
Metronidazole
Vancomycin
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
25 09 2020
25 09 2020
Historique:
received:
14
05
2020
accepted:
09
09
2020
entrez:
26
9
2020
pubmed:
27
9
2020
medline:
3
9
2021
Statut:
epublish
Résumé
Clostridioides (Clostridium) difficile is an important pathogen of healthcare- associated diarrhea, however, an increase in the occurrence of C. difficile infection (CDI) outside hospital settings has been reported. The accumulation of antimicrobial resistance in C. difficile can increase the risk of CDI development and/or its spread. The limited number of antimicrobials for the treatment of CDI is matter of some concern. In order to summarize the data on antimicrobial resistance to C. difficile derived from humans, a systematic review and meta-analysis were performed. We searched five bibliographic databases: (MEDLINE [PubMed], Scopus, Embase, Cochrane Library and Web of Science) for studies that focused on antimicrobial susceptibility testing in C. difficile and were published between 1992 and 2019. The weighted pooled resistance (WPR) for each antimicrobial agent was calculated using a random- effects model. A total of 111 studies were included. The WPR for metronidazole and vancomycin was 1.0% (95% CI 0-3%) and 1% (95% CI 0-2%) for the breakpoint > 2 mg/L and 0% (95% CI 0%) for breakpoint ≥32 μg/ml. Rifampin and tigecycline had a WPRs of 37.0% (95% CI 18-58%) and 1% (95% CI 0-3%), respectively. The WPRs for the other antimicrobials were as follows: ciprofloxacin 95% (95% CI 85-100%), moxifloxacin 32% (95% CI 25-40%), clindamycin 59% (95% CI 53-65%), amoxicillin/clavulanate 0% (0-0%), piperacillin/tazobactam 0% (0-0%) and ceftriaxone 47% (95% CI 29-65%). Tetracycline had a WPR 20% (95% CI 14-27%) and meropenem showed 0% (95% CI 0-1%); resistance to fidaxomicin was reported in one isolate (0.08%). Resistance to metronidazole, vancomycin, fidaxomicin, meropenem and piperacillin/tazobactam is reported rarely. From the alternative CDI drug treatments, tigecycline had a lower resistance rate than rifampin. The high-risk antimicrobials for CDI development showed a high level of resistance, the highest was seen in the second generation of fluoroquinolones and clindamycin; amoxicillin/clavulanate showed almost no resistance. Tetracycline resistance was present in one fifth of human clinical C. difficile isolates.
Sections du résumé
BACKGROUND
Clostridioides (Clostridium) difficile is an important pathogen of healthcare- associated diarrhea, however, an increase in the occurrence of C. difficile infection (CDI) outside hospital settings has been reported. The accumulation of antimicrobial resistance in C. difficile can increase the risk of CDI development and/or its spread. The limited number of antimicrobials for the treatment of CDI is matter of some concern.
OBJECTIVES
In order to summarize the data on antimicrobial resistance to C. difficile derived from humans, a systematic review and meta-analysis were performed.
METHODS
We searched five bibliographic databases: (MEDLINE [PubMed], Scopus, Embase, Cochrane Library and Web of Science) for studies that focused on antimicrobial susceptibility testing in C. difficile and were published between 1992 and 2019. The weighted pooled resistance (WPR) for each antimicrobial agent was calculated using a random- effects model.
RESULTS
A total of 111 studies were included. The WPR for metronidazole and vancomycin was 1.0% (95% CI 0-3%) and 1% (95% CI 0-2%) for the breakpoint > 2 mg/L and 0% (95% CI 0%) for breakpoint ≥32 μg/ml. Rifampin and tigecycline had a WPRs of 37.0% (95% CI 18-58%) and 1% (95% CI 0-3%), respectively. The WPRs for the other antimicrobials were as follows: ciprofloxacin 95% (95% CI 85-100%), moxifloxacin 32% (95% CI 25-40%), clindamycin 59% (95% CI 53-65%), amoxicillin/clavulanate 0% (0-0%), piperacillin/tazobactam 0% (0-0%) and ceftriaxone 47% (95% CI 29-65%). Tetracycline had a WPR 20% (95% CI 14-27%) and meropenem showed 0% (95% CI 0-1%); resistance to fidaxomicin was reported in one isolate (0.08%).
CONCLUSION
Resistance to metronidazole, vancomycin, fidaxomicin, meropenem and piperacillin/tazobactam is reported rarely. From the alternative CDI drug treatments, tigecycline had a lower resistance rate than rifampin. The high-risk antimicrobials for CDI development showed a high level of resistance, the highest was seen in the second generation of fluoroquinolones and clindamycin; amoxicillin/clavulanate showed almost no resistance. Tetracycline resistance was present in one fifth of human clinical C. difficile isolates.
Identifiants
pubmed: 32977835
doi: 10.1186/s13756-020-00815-5
pii: 10.1186/s13756-020-00815-5
pmc: PMC7517813
doi:
Substances chimiques
Anti-Bacterial Agents
0
Fluoroquinolones
0
Clindamycin
3U02EL437C
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
158Références
J Med Microbiol. 2010 Mar;59(Pt 3):338-344
pubmed: 19942691
Int J Med Microbiol. 2018 Apr;308(3):358-363
pubmed: 29478838
Vet J. 2015 Dec;206(3):349-55
pubmed: 26545846
J Antimicrob Chemother. 2016 Aug;71(8):2213-7
pubmed: 27130808
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
BMC Infect Dis. 2014 Nov 26;14:607
pubmed: 25425433
Anaerobe. 2015 Feb;31:47-9
pubmed: 25139122
J Antimicrob Chemother. 2018 Aug 1;73(8):2078-2084
pubmed: 29718329
Am J Infect Control. 2009 Dec;37(10):864-6
pubmed: 19712999
J Antimicrob Chemother. 2011 Oct;66(10):2227-34
pubmed: 21771851
Diagn Microbiol Infect Dis. 2016 Apr;84(4):361-5
pubmed: 26867962
Anaerobe. 2016 Aug;40:95-9
pubmed: 27370902
Antimicrob Agents Chemother. 2006 Oct;50(10):3473-5
pubmed: 17005836
Anaerobe. 2018 Dec;54:55-60
pubmed: 30053486
Eur J Clin Microbiol Infect Dis. 2010 Oct;29(10):1265-70
pubmed: 20577773
Anaerobe. 2014 Aug;28:85-9
pubmed: 24907488
New Microbes New Infect. 2015 Oct 09;8:99-102
pubmed: 26649183
Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26
pubmed: 24118601
J Med Microbiol. 2012 May;61(Pt 5):693-700
pubmed: 22301615
Chin Med J (Engl). 2014;127(9):1601-7
pubmed: 24791861
Int J Infect Dis. 2018 Feb;67:86-91
pubmed: 28736259
PLoS One. 2015 May 22;10(5):e0127026
pubmed: 26000789
Anaerobe. 2017 Apr;44:73-77
pubmed: 28188880
J Hosp Infect. 2005 Sep;61(1):11-4
pubmed: 16002183
Antimicrob Resist Infect Control. 2017 Jun 8;6:58
pubmed: 28603609
Front Microbiol. 2017 Dec 22;8:2584
pubmed: 29312258
Antimicrob Agents Chemother. 2012 Jul;56(7):3943-9
pubmed: 22508299
Iran Biomed J. 2015;19(3):143-8
pubmed: 26048022
Antonie Van Leeuwenhoek. 2011 Feb;99(2):249-55
pubmed: 20623188
Anaerobe. 2015 Dec;36:88-90
pubmed: 26256807
J Antimicrob Chemother. 2003 Mar;51(3):599-603
pubmed: 12615860
Lancet Infect Dis. 2017 Apr;17(4):411-421
pubmed: 28130063
Antimicrob Agents Chemother. 2019 Sep 16;:
pubmed: 31527041
J Clin Microbiol. 2012 Mar;50(3):915-21
pubmed: 22205786
J Hosp Infect. 2018 Aug;99(4):475-480
pubmed: 29604298
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28137804
J Clin Microbiol. 2011 Dec;49(12):4319-21
pubmed: 21998414
Med Mal Infect. 2013 Feb;43(2):67-74
pubmed: 23498135
Anaerobe. 2017 Jun;45:106-113
pubmed: 28216085
Eur J Clin Microbiol Infect Dis. 2013 Aug;32(8):1027-30
pubmed: 23443474
Diagn Microbiol Infect Dis. 2018 Nov;92(3):250-252
pubmed: 30042035
Anaerobe. 2019 Dec;60:102094
pubmed: 31499177
Infect Drug Resist. 2018 Aug 15;11:1197-1203
pubmed: 30147348
J Med Microbiol. 2013 Sep;62(Pt 9):1478-1485
pubmed: 23861298
PLoS One. 2016 Mar 24;11(3):e0151964
pubmed: 27011211
J Infect Chemother. 2018 Aug;24(8):641-647
pubmed: 29685855
Antimicrob Resist Infect Control. 2019 Jan 14;8:12
pubmed: 30675339
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1053-1058
pubmed: 31927652
J Med Microbiol. 2018 Jan;67(1):52-59
pubmed: 29160203
Antimicrob Agents Chemother. 2015 Nov 02;60(1):418-23
pubmed: 26525793
J Clin Microbiol. 2017 Mar;55(3):801-810
pubmed: 27974547
Anaerobe. 2015 Feb;31:37-41
pubmed: 25242196
Antimicrob Agents Chemother. 2014 Jul;58(7):4214-8
pubmed: 24752264
New Microbiol. 2012 Jul;35(3):307-16
pubmed: 22842600
Curr Microbiol. 2019 Apr;76(4):520-526
pubmed: 30805700
Clin Microbiol Infect. 2018 May;24(5):469-475
pubmed: 29274463
Eur J Clin Microbiol Infect Dis. 2008 Dec;27(12):1201-7
pubmed: 18560909
J Clin Pathol. 2010 Apr;63(4):355-8
pubmed: 20354207
Anaerobe. 2010 Dec;16(6):633-5
pubmed: 20849968
Folia Microbiol (Praha). 2014 May;59(3):209-15
pubmed: 24114414
Clin Microbiol Infect. 2015 Mar;21(3):248.e9-248.e16
pubmed: 25701178
Antimicrob Agents Chemother. 2002 Jun;46(6):1647-50
pubmed: 12019070
J Antimicrob Chemother. 2015 Nov;70(11):2992-9
pubmed: 26221017
Infez Med. 2018 Dec 1;26(4):308-315
pubmed: 30555133
Scand J Infect Dis. 2012 Apr;44(4):243-9
pubmed: 22077148
J Glob Antimicrob Resist. 2019 Mar;16:53-58
pubmed: 30266640
J Med Microbiol. 2014 Feb;63(Pt 2):322-324
pubmed: 24287669
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
Epidemiol Infect. 2016 Jan;144(1):161-70
pubmed: 25989816
PLoS One. 2012;7(3):e31559
pubmed: 22396735
Gut. 2019 Jul;68(7):1224-1231
pubmed: 30254135
Int J Antimicrob Agents. 2016 Dec;48(6):736-739
pubmed: 27793509
J Diarrhoeal Dis Res. 1992 Sep;10(3):156-8
pubmed: 1430970
Folia Microbiol (Praha). 2017 Sep;62(5):445-451
pubmed: 28332133
BMC Infect Dis. 2016 Jun 22;16:309
pubmed: 27334992
J Med Microbiol. 2008 Jun;57(Pt 6):784-789
pubmed: 18480338
Nat Rev Microbiol. 2009 Jul;7(7):526-36
pubmed: 19528959
Emerg Microbes Infect. 2016 May 11;5:e42
pubmed: 27165560
J Clin Microbiol. 2014 Dec;52(12):4260-6
pubmed: 25275005
PLoS One. 2016 Aug 18;11(8):e0161411
pubmed: 27536994
Diagn Microbiol Infect Dis. 2018 Jul;91(3):275-281
pubmed: 29571838
Int J Antimicrob Agents. 2012 Jul;40(1):24-9
pubmed: 22578765
Braz J Infect Dis. 2016 Sep-Oct;20(5):476-81
pubmed: 27542867
New Microbes New Infect. 2016 Sep 16;14:58-66
pubmed: 27752322
Anaerobe. 2018 Dec;54:146-150
pubmed: 30261271
mBio. 2019 Mar 12;10(2):
pubmed: 30862754
J Glob Antimicrob Resist. 2017 Sep;10:161-164
pubmed: 28729205
Lancet Infect Dis. 2017 Feb;17(2):194-206
pubmed: 27825595
Clin Microbiol Infect. 2018 May;24(5):452-462
pubmed: 29309934
Diagn Microbiol Infect Dis. 2018 Jun;91(2):105-111
pubmed: 29456070
J Med Microbiol. 2003 Dec;52(Pt 12):1095-1099
pubmed: 14614068
Euro Surveill. 2016 Jul 21;21(29):
pubmed: 27487436
Anaerobe. 2019 Dec;60:102050
pubmed: 31173889
Vet Microbiol. 2017 Feb;199:15-22
pubmed: 28110780
Anaerobe. 2019 Aug;58:35-46
pubmed: 31330183
BMC Infect Dis. 2019 Mar 7;19(1):232
pubmed: 30845918
J Glob Antimicrob Resist. 2019 Sep;18:28-33
pubmed: 30703583
PLoS One. 2013 Oct 07;8(10):e75471
pubmed: 24116048
Int J Antimicrob Agents. 2013 Jan;41(1):80-4
pubmed: 23148985
Antimicrob Agents Chemother. 2015 Nov 23;60(2):789-96
pubmed: 26596936
Infect Drug Resist. 2018 Apr 06;11:489-500
pubmed: 29670381
Nat Microbiol. 2019 Sep;4(9):1450-1456
pubmed: 31133751
J Med Microbiol. 2007 Jul;56(Pt 7):921-929
pubmed: 17577057
Epidemiol Infect. 2012 Oct;140(10):1787-93
pubmed: 22152928
Anaerobe. 2018 Aug;52:75-78
pubmed: 29890209
Anaerobe. 2019 Dec;60:102106
pubmed: 31655214
Diagn Microbiol Infect Dis. 2017 Oct;89(2):161-163
pubmed: 28800896
Sci Rep. 2017 Dec 8;7(1):17218
pubmed: 29222426
Antimicrob Agents Chemother. 2012 Jun;56(6):2929-32
pubmed: 22411613
Int J Antimicrob Agents. 2009 Apr;33(4):339-42
pubmed: 19097757
Clin Microbiol Infect. 2019 May;25(5):588-594
pubmed: 30616013
Anaerobe. 2017 Dec;48:262-268
pubmed: 29066337
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4896-900
pubmed: 27270275
PLoS One. 2016 Jan 25;11(1):e0147601
pubmed: 26808317
Clin Microbiol Infect. 2016 Aug;22(8):695-700
pubmed: 27091093
Anaerobe. 2019 Feb;55:35-39
pubmed: 30391527
Iran Red Crescent Med J. 2013 Aug;15(8):704-11
pubmed: 24578839
Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):763-72
pubmed: 25471195
Anaerobe. 2016 Apr;38:97-102
pubmed: 26802875
Antimicrob Agents Chemother. 2015 Oct;59(10):6437-43
pubmed: 26239985
Int J Antimicrob Agents. 2018 May;51(5):762-767
pubmed: 29408226
Anaerobe. 2017 Dec;48:232-236
pubmed: 28987390
N Z Med J. 2011 Apr 15;124(1332):45-51
pubmed: 21747423
Future Sci OA. 2020 Jan 27;6(3):FSO438
pubmed: 32140243
Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2
pubmed: 15155234
Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9
pubmed: 17517836
Afr J Lab Med. 2018 Dec 06;7(2):846
pubmed: 30568907
Int J Antimicrob Agents. 2002 Oct;20(4):270-4
pubmed: 12385683
J Antimicrob Chemother. 2011 Dec;66(12):2850-5
pubmed: 21948965
J Microbiol Immunol Infect. 2018 Jun;51(3):411-416
pubmed: 28693926
Medicine (Baltimore). 2018 Jun;97(25):e11219
pubmed: 29924052
J Appl Microbiol. 2018 Nov;125(5):1518-1525
pubmed: 29957893
Anaerobe. 2014 Dec;30:18-23
pubmed: 25079669